secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001082554-23-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics reports record 2022 revenue of $1.94B, up 15% YoY; Q4 EPS $2.67
--------------------------------------------------------------------------------

- Full year total revenues $1.94B, up 15% YoY; net income $727.3M ($15.00 diluted EPS).
- Q4 revenues $491.5M, net income $132.1M ($2.67 diluted EPS).
- Tyvaso net product sales $873M for 2022, up 44% YoY driven by Tyvaso DPI launch and PH-ILD expansion.
- Treprostinil product sales grew 19% in 2022; company targets $4B revenue run rate by end of 2025.
- Unituxin sales declined 10% to $182.9M; Adcirca down 26% due to generic competition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255423000007/0001082554-23-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255423000007/uthr-20230222.htm
  HTML page:      https://secwatch.observer/filing/0001082554-23-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer